Intragastric Balloon Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035

The Global Intragastric Balloon Market was valued at USD 77.5 million in 2025 and is estimated to grow at a CAGR of 15.2% to reach USD 312.9 million by 2035.

The market growth is supported by rising obesity prevalence, improved clinical awareness, expanding access to weight management treatments, and increasing insurance coverage for obesity-related interventions. Continuous advancements in medical device technology are also improving treatment outcomes and patient acceptance. Intragastric balloons are minimally invasive, non-surgical weight-loss devices placed in the stomach to reduce food intake by creating a feeling of fullness. They are generally recommended for individuals who have not achieved results through diet and exercise alone. These devices are inserted endoscopically or in capsule form and removed after a defined treatment period. Ongoing innovation in balloon design, including adjustable systems and swallowable capsule technologies, is enhancing safety, comfort, and procedural efficiency. Integration of digital health tools and remote patient monitoring is further improving post-procedure care and treatment adherence. Expansion of specialized obesity management clinics is also supporting broader adoption across healthcare systems.

The single intragastric balloon segment held a 60.2% share in 2025 owing to its established clinical usage, easier insertion and removal process, and lower complication risk compared to multi-balloon systems. These devices are widely preferred because they offer a straightforward implantation procedure that reduces procedural time and enhances patient convenience. Their simplicity also allows healthcare providers to perform treatments more efficiently while maintaining safety standards. As a result, single balloon systems continue to be the most widely used option in weight-loss interventions, supported by strong physician preference and proven clinical outcomes.

The saline-filled balloon segment generated USD 54.6 million in 2025 and is projected to grow at a CAGR of 14.8% through 2035. This segment is widely preferred due to its strong safety profile and reliable performance in weight management treatments. In case of leakage or rupture, saline-filled systems pose minimal risk as the solution is safely absorbed by the body. These balloons also provide controlled inflation and greater stability during use, reducing the likelihood of deflation-related complications. Their consistent performance and improved safety characteristics make them a trusted choice among healthcare professionals and patients seeking non-surgical weight loss solutions.

North America Intragastric Balloon Market held a 38.9% share in 2025, driven by a high prevalence of obesity and increasing demand for non-invasive weight management solutions. Lifestyle factors such as sedentary behavior and high-calorie diets have significantly contributed to rising obesity rates across the region. This has increased the burden of obesity-related conditions, encouraging early intervention strategies. Healthcare providers in the region are increasingly adopting intragastric balloons as an alternative to bariatric surgery for eligible patients, supporting steady market expansion across clinical settings.

Major players operating in the Global Intragastric Balloon Industry are Allurion, Boston Scientific, ReShape Lifesciences, SPATZ, Medispar, SILIMED, Endalis, HELIOSCOPIE, Districlass Medical, Beijing ZKSK Technology, SHENYUN, Suzhou Shenyun Medical, Medicone, HEALTH WARE. Companies in the Intragastric Balloon Market are focusing on strengthening their market position through continuous product innovation and the development of safer, more comfortable, and minimally invasive weight-loss devices. Strategic partnerships with hospitals, bariatric clinics, and healthcare providers are being used to expand clinical adoption and improve patient access. Firms are investing heavily in research and development to introduce adjustable and swallowable balloon technologies that enhance treatment efficiency and reduce procedural complexity. Expansion into emerging healthcare markets is also supporting revenue growth and broader geographic reach. In addition, companies are integrating digital health platforms and remote monitoring tools to improve patient follow-up and treatment outcomes. Strong emphasis is being placed on clinical trials and regulatory approvals to build trust and strengthen product credibility.